PepGen Inc. (PEPG)
2.47
+0.15
(+6.47%)
USD |
NASDAQ |
Nov 06, 16:00
2.51
+0.04
(+1.62%)
After-Hours: 20:00
PepGen Research and Development Expense (Quarterly) : 12.22M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.22M |
| March 31, 2026 | 12.68M |
| December 31, 2025 | 13.52M |
| September 30, 2025 | 13.08M |
| June 30, 2025 | 18.06M |
| March 31, 2025 | 24.99M |
| December 31, 2024 | 18.58M |
| September 30, 2024 | 17.34M |
| June 30, 2024 | 24.69M |
| March 31, 2024 | 14.36M |
| December 31, 2023 | 15.95M |
| September 30, 2023 | 20.19M |
| Date | Value |
|---|---|
| June 30, 2023 | 16.60M |
| March 31, 2023 | 14.21M |
| December 31, 2022 | 13.02M |
| September 30, 2022 | 15.82M |
| June 30, 2022 | 14.10M |
| March 31, 2022 | 10.64M |
| December 31, 2021 | 4.493M |
| September 30, 2021 | 5.666M |
| March 31, 2021 | 5.493M |
| December 31, 2020 | 0.426M |
| September 30, 2020 | 0.116M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 42.14M |
| IRulya Therapeutics, Inc. | 5.461M |
| Q32 Bio, Inc. | 5.149M |
| Bridgebio Oncology Therapeutics, Inc. | 49.22M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |